Flow Diversion Aneurysm Treatment

Global Flow Diversion Aneurysm Treatment Market to Reach US$8.2 Billion by 2030

The global market for Flow Diversion Aneurysm Treatment estimated at US$5.3 Billion in the year 2024, is expected to reach US$8.2 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Flow-Diverting Stents, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Intrasaccular Flow Disruption Devices segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 7.6% CAGR

The Flow Diversion Aneurysm Treatment market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Global Flow Diversion in Aneurysm Treatment – Key Trends & Drivers Summarized

Why Is Flow Diversion Transforming the Management of Intracranial Aneurysms?
Flow diversion has emerged as a breakthrough technique in the treatment of intracranial aneurysms, particularly for wide-neck, large, fusiform, and previously untreatable aneurysms that pose challenges for conventional clipping or coiling methods. Unlike traditional endovascular coiling that fills the aneurysm sac directly, flow diverters are stent-like devices implanted within the parent artery to redirect blood flow away from the aneurysm. This promotes intra-aneurysmal thrombosis and vascular remodeling, leading to gradual occlusion and long-term stabilization of the aneurysm wall.

The minimally invasive nature of this approach, combined with its efficacy in complex and unruptured aneurysms, has positioned flow diversion as a preferred strategy in neurointervention. Clinical adoption has surged in response to increasing awareness of its favorable long-term outcomes, reduced retreatment rates, and applicability to challenging anatomical regions such as the internal carotid artery. As neurological imaging and intervention capabilities evolve, flow diversion is being integrated into early-stage treatment planning, especially for aneurysms previously considered inoperable.

What Innovations Are Enhancing the Efficacy and Safety of Flow Diverters?
Technological advancements in flow diverter design and delivery systems are playing a critical role in improving procedural outcomes and safety profiles. The latest generation of flow diverters features lower-profile systems compatible with smaller microcatheters, allowing for better navigability through tortuous intracranial vasculature. Innovations such as resheathable and repositionable devices give neurointerventionists greater control during deployment, reducing the risk of malposition or vessel injury.

Surface modifications and anti-thrombotic coatings—such as phosphorylcholine or hydrophilic polymer coatings—are being adopted to enhance hemocompatibility and reduce reliance on long-term dual antiplatelet therapy. Some next-gen flow diverters are even bioresorbable, designed to degrade once vascular remodeling is achieved, minimizing long-term implant risks. Additionally, imaging-guided navigation systems, including 3D rotational angiography and roadmap fluoroscopy, are improving the precision and confidence of device placement. These innovations are enabling treatment of aneurysms in previously inaccessible or high-risk locations, including distal vessels and bifurcation points.

Which Patient Populations and Clinical Settings Are Driving Demand for Flow Diversion?
Flow diversion is most commonly employed for unruptured intracranial aneurysms in adult patients, particularly in the anterior circulation (e.g., internal carotid artery). However, growing clinical evidence is expanding its use in posterior circulation aneurysms, recurrent aneurysms post-coiling, and selected cases of ruptured aneurysms under compassionate use or advanced center protocols. The approach is especially beneficial for patients with large or giant aneurysms, where coiling would be less effective or technically challenging.

Tertiary and quaternary care centers equipped with specialized neurointerventional capabilities are the primary sites of adoption, although the technique is gradually being disseminated to regional and community hospitals as training and device availability improve. Increased detection of asymptomatic aneurysms through incidental brain imaging is also contributing to earlier intervention using flow diversion. Meanwhile, aging populations and increasing stroke awareness are expanding the eligible patient base, as early identification and elective treatment of aneurysms gain clinical traction.

What Are the Primary Drivers Supporting Growth in the Flow Diversion Market?
The growth in the flow diversion aneurysm treatment market is driven by several key factors related to procedural efficacy, clinical demand, and product innovation. A major driver is the expanding body of real-world evidence and long-term follow-up data demonstrating high occlusion rates, low retreatment needs, and favorable neurological outcomes. As neurointervention shifts toward minimally invasive solutions with durable results, flow diversion aligns well with both clinician and patient expectations.

In parallel, improvements in device flexibility, deliverability, and safety features are broadening the anatomical range and complexity of aneurysms that can be treated with flow diversion. Rising investments in stroke and neurovascular intervention infrastructure—particularly in emerging economies—are also facilitating broader access to advanced aneurysm therapies. Moreover, continuous training, proctoring, and certification programs by device manufacturers and academic centers are accelerating clinical adoption. Together, these drivers are reinforcing flow diversion as a cornerstone technique in the next-generation management of cerebral aneurysms.

SCOPE OF STUDY:

The report analyzes the Flow Diversion Aneurysm Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Flow-Diverting Stents, Intrasaccular Flow Disruption Devices); End-Use (Hospitals End-Use, Specialty Clinics End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Acandis GmbH
• BALT Group
• Cardinal Health Inc.
• Endologix LLC
• Evasc Medical Systems Corp.
• Imperative Care Inc.
• InspireMD Inc.
• Johnson & Johnson Services Inc.
• Kaneka Corporation
• Lepu Medical Technology Co. Ltd.
• Medtronic Plc
• Merlin MD Pte. Ltd.
• MicroPort Scientific Corporation
• MicroVention Inc. (Terumo)
• Mizuho Medical Co., Ltd.
• Oxford Endovascular Ltd.
• Penumbra Inc.
• Phenox GmbH
• Rapid Medical Ltd.
• Sequent Medical Inc.
• Siemens AG
• Stryker Corporation
• Terumo Corporation
• Wallaby Medical LLC
• W.L. Gore & Associates, Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.